Alnylam Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($1.18) Per Share, Leerink Swann Forecasts (NASDAQ:ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) – Stock analysts at Leerink Swann cut their Q3 2017 earnings per share (EPS) estimates for Alnylam Pharmaceuticals in a report released on Wednesday. Leerink Swann analyst P. Matteis now expects that the biopharmaceutical company will post earnings of ($1.18) per share for the quarter, down from their prior forecast of ($1.11). Leerink Swann currently has a “Market Perform” rating and a $67.00 target price on the stock. Leerink Swann also issued estimates for Alnylam Pharmaceuticals’ Q4 2017 earnings at ($1.10) EPS, FY2017 earnings at ($4.86) EPS and FY2018 earnings at ($5.21) EPS.
Alnylam Pharmaceuticals (NASDAQ:ALNY) last issued its quarterly earnings data on Wednesday, August 9th. The biopharmaceutical company reported ($1.34) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.22) by $0.12. Alnylam Pharmaceuticals had a negative return on equity of 45.53% and a negative net margin of 670.81%. The company had revenue of $15.93 million during the quarter, compared to the consensus estimate of $23.86 million. During the same quarter last year, the company posted ($1.05) earnings per share. The firm’s revenue for the quarter was up 82.9% compared to the same quarter last year. ILLEGAL ACTIVITY WARNING: “Alnylam Pharmaceuticals, Inc. to Post Q3 2017 Earnings of ($1.18) Per Share, Leerink Swann Forecasts (NASDAQ:ALNY)” was originally published by American Banking News and is the property of of American Banking News. If you are accessing this report on another domain, it was illegally stolen and republished in violation of international copyright legislation. The correct version of this report can be read at https://www.americanbankingnews.com/2017/08/14/alnylam-pharmaceuticals-inc-to-post-q3-2017-earnings-of-1-18-per-share-leerink-swann-forecasts-nasdaqalny.html.
A number of other analysts have also issued reports on ALNY. Chardan Capital reissued a “buy” rating and set a $124.00 target price (down from $131.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday. BidaskClub raised shares of Alnylam Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, August 5th. Stifel Nicolaus reissued a “buy” rating and set a $56.00 target price (up from $47.00) on shares of Alnylam Pharmaceuticals in a research note on Thursday. Sanford C. Bernstein assumed coverage on shares of Alnylam Pharmaceuticals in a research note on Thursday, July 27th. They set an “outperform” rating and a $99.00 target price for the company. Finally, Morgan Stanley boosted their target price on shares of Alnylam Pharmaceuticals from $46.00 to $50.00 and gave the company an “equal weight” rating in a research note on Thursday. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, thirteen have assigned a buy rating and one has given a strong buy rating to the company. Alnylam Pharmaceuticals presently has a consensus rating of “Buy” and an average price target of $81.74.
Alnylam Pharmaceuticals (NASDAQ ALNY) opened at 78.22 on Monday. The firm has a 50-day moving average of $80.94 and a 200 day moving average of $61.92. The company’s market capitalization is $7.18 billion. Alnylam Pharmaceuticals has a one year low of $31.38 and a one year high of $86.92.
A number of institutional investors have recently made changes to their positions in ALNY. DekaBank Deutsche Girozentrale increased its position in shares of Alnylam Pharmaceuticals by 61.3% in the first quarter. DekaBank Deutsche Girozentrale now owns 65,360 shares of the biopharmaceutical company’s stock worth $3,342,000 after buying an additional 24,850 shares in the last quarter. Canada Pension Plan Investment Board increased its position in shares of Alnylam Pharmaceuticals by 120.3% in the first quarter. Canada Pension Plan Investment Board now owns 81,472 shares of the biopharmaceutical company’s stock worth $4,175,000 after buying an additional 44,486 shares in the last quarter. Rockefeller Financial Services Inc. increased its position in shares of Alnylam Pharmaceuticals by 4,724.4% in the first quarter. Rockefeller Financial Services Inc. now owns 506,223 shares of the biopharmaceutical company’s stock worth $25,944,000 after buying an additional 495,730 shares in the last quarter. Russell Investments Group Ltd. increased its position in shares of Alnylam Pharmaceuticals by 341.1% in the first quarter. Russell Investments Group Ltd. now owns 277,339 shares of the biopharmaceutical company’s stock worth $14,214,000 after buying an additional 214,470 shares in the last quarter. Finally, NBT Bank N A NY purchased a new position in shares of Alnylam Pharmaceuticals during the first quarter worth approximately $313,000. Institutional investors and hedge funds own 88.99% of the company’s stock.
In other Alnylam Pharmaceuticals news, EVP Akshay Vaishnaw sold 11,000 shares of the business’s stock in a transaction dated Tuesday, May 23rd. The shares were sold at an average price of $75.00, for a total value of $825,000.00. Following the completion of the transaction, the executive vice president now directly owns 21,297 shares in the company, valued at $1,597,275. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Laurie Keating bought 11,500 shares of Alnylam Pharmaceuticals stock in a transaction on Tuesday, May 30th. The stock was purchased at an average price of $65.35 per share, with a total value of $751,525.00. Following the completion of the acquisition, the senior vice president now directly owns 11,500 shares of the company’s stock, valued at approximately $751,525. The disclosure for this purchase can be found here. Insiders own 4.30% of the company’s stock.
About Alnylam Pharmaceuticals
Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs).
Receive News & Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.